Our lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size and improve visual acuity. Nyxol is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia.
Nyxol is an investigational 505(b)(2) product candidate that has been studied in over 230 subjects across 7 completed Phase 1 and 2 trials.